Skip to main content

Table 1 Clinicopathological characteristics of the EAC study population with BE

From: LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's Esophagus?

Characteristics

Patients

(n = 41)

LgR5

Barrett's esophagus*

p-value

LgR5

Barrett's EAC

p-value

  

low

high

 

low

high

 

Age (y)

   

.100

  

.051

<66

21 (51%)

10 (48%)

11 (52%)

 

4 (19%)

17 (81%)

 

≥66

20 (49%)

4 (20%)

16 (80%)

 

10 (50%)

10 (50%)

 

Gender

   

.074

  

.673

Male

34 (83%)

14 (41%)

20 (59%)

 

11 (32%)

23 (68%)

 

Female

7 (17%)

0 (0%)

7 (100%)

 

3 (43%)

4 (57%)

 

Histological Grading

   

.305a

  

.083a

G1

11 (27%)

6 (55%)

5 (45%)

 

6 (55%)

5 (45%)

 

G2

16 (39%)

5 (31%)

11 (69%)

 

6 (37%)

10 (63%)

 

G3/4

14(34%)

3 (21%)

11 (79%)

 

2 (14%)

12 (86%)

 

Depth of invasion

   

.481b

  

.155b

pT1

10 (24%)

4 (40%)

6 (60%)

 

6 (60%)

4 (40%)

 

pT2

18 (44%)

7 (39%)

11 (61%)

 

6 (33%)

12 (67%)

 

pT3

6 (15%)

1 (17%)

5 (83%)

 

1 (17%)

5 (83%)

 

pT4

7 (17%)

2 (28%)

5 (72%)

 

1 (14%)

6 (86%)

 

Lymph node metastases

   

.001

  

.0154

pN0

15 (37%)

10 (67%)

5 (33%)

 

9 (60%)

6 (40%)

 

pN1-3

26 (63%)

4 (15%)

22 (85%)

 

5 (19%)

21 (81%)

 

UICC stage

   

.481c

  

.155c

UICC I

9 (22%)

4 (44%)

5 (56%)

 

2 (22%)

4 (78%)

 

UICC II

19 (46%)

7 (37%)

12 (63%)

 

7 (37%)

12 (63%)

 

UICC III

13 (31%)

3 (23%)

10 (77%)

 

5 (15%)

11 (85%)

 

UICC IV

0 (0%)

0 (0%)

0 (0%)

 

0 (0%)

0 (0%)

 

Median OS (m)

42 m

32 (n = 14)

24 (n = 27)

 

33 (n = 14)

28 (n = 27)

 
  1. Abbrevations: EAC, esophageal adenocarcinomas; BE, Barrett metaplasia; y, years; G, grading; UICC, International Union against Cancer; R, residual tumor; OS, overall survival; m, months. *Clinico-pathological features of BE are related to adjacent EAC.
  2. aG1/2 vs. GT3/4; bpT1/2 vs. pT3/4; cUICC I/II vs. UICC III/IV